WEKO3
アイテム
{"_buckets": {"deposit": "4a41b125-c231-488d-a1cc-a1a246140d07"}, "_deposit": {"created_by": 1, "id": "48414", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "48414"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00048414", "sets": ["1"]}, "author_link": ["486674", "486670", "486671", "486667", "486673", "486675", "486664", "486669", "486662", "486663", "486668", "486672", "486666", "486665"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2017-09", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "54", "bibliographicPageEnd": "88826", "bibliographicPageStart": "88815", "bibliographicVolumeNumber": "8", "bibliographic_titles": [{"bibliographic_title": "Oncotarget"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is an\nantiangiogenic agent clinically used for various cancers. However, repeated use of\nthis agent leads to tumor-decreased vascularity and hypoxia with activation of an\nHIF-1 signaling pathway, which results in drug delivery deficiency and induction of\nmalignant behaviors in tumors. Here, we developed a novel strategy to treat tumors\nwith bevacizumab-induced vascular decrease and hypoxia using 64Cu-diacetyl-bis\n(N4-methylthiosemicarbazone) (64Cu-ATSM), a potential theranostic agent, which\npossesses high tissue permeability and can target over-reduced conditions under\nhypoxia in tumors, with a human colon carcinoma HT-29 tumor-bearing mouse model.\nThe long-term treatment with bevacizumab caused decreased blood vessel density\nand activation of an HIF-1 signaling pathway; increased uptake of 64Cu-ATSM was also\nobserved despite limited blood vessel density in HT-29 tumors. In vivo high-resolution\nSPECT/PET/CT imaging confirmed reduced vascularity and increased proportion of\n64Cu-ATSM uptake areas within the bevacizumab-treated tumors. 64Cu-ATSM therapy\nwas effective to inhibit tumor growth and prolong survival of the bevacizumab-treated\ntumor-bearing mice without major adverse effects. In conclusion, 64Cu-ATSM therapy\neffectively enhanced anti-tumor effects in tumors with bevacizumab-induced vascular\ndecrease and hypoxia. 64Cu-ATSM therapy could represent a novel approach as an add-on to antiangiogenic therapy.", "subitem_description_type": "Abstract"}]}, "item_8_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Inpact Journals"}]}, "item_8_relation_13": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "29179478", "subitem_relation_type_select": "PMID"}}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.18632/oncotarget.21323", "subitem_relation_type_select": "DOI"}}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Yoshii, Yukie"}], "nameIdentifiers": [{"nameIdentifier": "486662", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshimoto, Mitsuyoshi"}], "nameIdentifiers": [{"nameIdentifier": "486663", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsumoto, Hiroki"}], "nameIdentifiers": [{"nameIdentifier": "486664", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Furukawa, Takako"}], "nameIdentifiers": [{"nameIdentifier": "486665", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Zhang, Ming-Rong"}], "nameIdentifiers": [{"nameIdentifier": "486666", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Inubushi, Masayuki"}], "nameIdentifiers": [{"nameIdentifier": "486667", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "486668", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Fujibayashi, Yasuhisa"}], "nameIdentifiers": [{"nameIdentifier": "486669", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Higashi, Tatsuya"}], "nameIdentifiers": [{"nameIdentifier": "486670", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Saga, Tsuneo"}], "nameIdentifiers": [{"nameIdentifier": "486671", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "吉井 幸恵", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "486672", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "張 明栄", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "486673", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "辻 厚至", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "486674", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "東 達也", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "486675", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts ", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts "}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/48414", "pubdate": {"attribute_name": "公開日", "attribute_value": "2017-12-07"}, "publish_date": "2017-12-07", "publish_status": "0", "recid": "48414", "relation": {}, "relation_version_is_last": true, "title": ["64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts "], "weko_shared_id": -1}
64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts
https://repo.qst.go.jp/records/48414
https://repo.qst.go.jp/records/484141125b2cc-416c-4079-8969-1803d323edf4
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2017-12-07 | |||||
タイトル | ||||||
タイトル | 64Cu-ATSM internal radiotherapy to treat tumors with bevacizumab-induced vascular decrease and hypoxia in human colon carcinoma xenografts | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Yoshii, Yukie
× Yoshii, Yukie× Yoshimoto, Mitsuyoshi× Matsumoto, Hiroki× Furukawa, Takako× Zhang, Ming-Rong× Inubushi, Masayuki× Tsuji, Atsushi× Fujibayashi, Yasuhisa× Higashi, Tatsuya× Saga, Tsuneo× 吉井 幸恵× 張 明栄× 辻 厚至× 東 達也 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody, is an antiangiogenic agent clinically used for various cancers. However, repeated use of this agent leads to tumor-decreased vascularity and hypoxia with activation of an HIF-1 signaling pathway, which results in drug delivery deficiency and induction of malignant behaviors in tumors. Here, we developed a novel strategy to treat tumors with bevacizumab-induced vascular decrease and hypoxia using 64Cu-diacetyl-bis (N4-methylthiosemicarbazone) (64Cu-ATSM), a potential theranostic agent, which possesses high tissue permeability and can target over-reduced conditions under hypoxia in tumors, with a human colon carcinoma HT-29 tumor-bearing mouse model. The long-term treatment with bevacizumab caused decreased blood vessel density and activation of an HIF-1 signaling pathway; increased uptake of 64Cu-ATSM was also observed despite limited blood vessel density in HT-29 tumors. In vivo high-resolution SPECT/PET/CT imaging confirmed reduced vascularity and increased proportion of 64Cu-ATSM uptake areas within the bevacizumab-treated tumors. 64Cu-ATSM therapy was effective to inhibit tumor growth and prolong survival of the bevacizumab-treated tumor-bearing mice without major adverse effects. In conclusion, 64Cu-ATSM therapy effectively enhanced anti-tumor effects in tumors with bevacizumab-induced vascular decrease and hypoxia. 64Cu-ATSM therapy could represent a novel approach as an add-on to antiangiogenic therapy. |
|||||
書誌情報 |
Oncotarget 巻 8, 号 54, p. 88815-88826, 発行日 2017-09 |
|||||
出版者 | ||||||
出版者 | Inpact Journals | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 29179478 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.18632/oncotarget.21323 |